Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jhKOgk
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Recent updating of the World Health Organization (WHO) classification of central nervous system (CNS) tumors in 2016 demonstrates...
-
In our previous work, the dichloromethane-methanol (1:1 v/v) extract, fractions and isolated compounds from Polyscias fulva stem bark showed...
-
Cincinnati.com No fooling; go get your head (and neck) examined for free Cincinnati.com Thursday, get your head examined. UC Health ...
-
Background Agricultural work can expose workers to increased risk of heat strain and volume depletion due to repeated exposures to high ambi...
-
Nursing students' perceptions of a video-based serious game's educational value: A pilot study. Nurse Educ Today. 2017 Dec 28;...
-
Anaphora is a rhetorical term for the repetition of a word or phrase at the beginning of successive clauses or verses. from #AlexandrosSfa...
-
Abstract We introduce a novel diagnostic Visual Voiding Device (VVD), which has the ability to visually document urinary voiding events an...
-
Method combines radiomics with three - compartment breast image analysis of dual - energy mammography (Source: The Doctors Lounge - Oncology...
-
Cone beam computerized tomography (CBCT) has been widely used in dental implanting. However, the local hospitals usually don’t have access t...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου